The Patent Finder
VU

Vilnius University

First filing 2011
OverviewNotableFeesChangesFamiliesPatent listSources & methods

32 patents currently held

5 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

The next term ends in Oct 2032. from the record

Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
Oct 2032
Next term end
22
Patent families

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
notable patents fee due within 90 days all others Updated Nov 19, 2026 · includes USPTO assignment data published Nov 18, 2026, status data published Nov 19, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.

Notable patents

Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
RNA-DIRECTED DNA CLEAVAGE BY THE Cas9-crRNA COMPLEX US 9,637,739
The most cited patent in this portfolio, cited by 426 later US patents, top 1% of utility patents granted in 2017 in our data. Protection runs to 2033.
Ends Mar 2033 · High confidence
Also notable
RNA-DIRECTED DNA CLEAVAGE BY THE Cas9-crRNA COMPLEX US 11,555,187
Cited by 87 later US patents, top 1% of utility patents granted in 2023 in our data. Protection runs to 2033. A terminal disclaimer caps this term to an earlier patent's.
Ends Mar 2033 · High confidence
Also notable
System and Method for a Biomimetic Fluid Processing US 11,396,016
A family of 6 related applications built on the 2022 grant. Protection runs to 2033. A terminal disclaimer caps this term to an earlier patent's.
Ends Nov 2033 · Medium confidence

Formerly held, still cited

Notable
Cited by 50 later US patents, top 5% of utility patents granted in 2020 in our data. Protection runs to 2035.
Ends Apr 2035 · High confidence

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 2 fees due Jan 9 to 30, 2027 · next Jan 9
  • 1 fee due Feb 20, 2027
    The maintenance fee for Programmable RNA Shredding by the Type III-A CRISPR-Cas System of Streptococcus Thermophilus (US 10,385,336) comes due Feb 20, 2027. Unpaid by Aug 20, 2027, it lapses early.
  • 1 fee due Jun 26, 2027
    The maintenance fee for System and Method for a Biomimetic Fluid Processing (US 11,850,589) comes due Jun 26, 2027. Unpaid by Dec 27, 2027, it lapses early.
  • 1 fee due Jul 2, 2027
    The maintenance fee for Systems and Methods for Encapsulation and Multi-Step Processing of Biological Samples (US 11,860,076) comes due Jul 2, 2027. Unpaid by Jan 3, 2028, it lapses early.
  • 1 fee due Sep 17, 2027
    The maintenance fee for Systems and Methods for Biomimetic Fluid Processing (US 10,590,373) comes due Sep 17, 2027. Unpaid by Mar 17, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

  • 1 of the patents on this record was granted since Aug 21, 2026

What they patent

The largest of its 22 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.

Patents held now

Soonest term end first.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatusExpiresConfidence
US 9,725,467Fluorinated Benzenesulfonamides as Inhibitors of Carbonic Anhydrase
In force (reinstated)
 · High confidence
In force (reinstated)High confidence
US 9,347,093Nucleic Acid Production and Sequence Analysis
In force
 · High confidence
In forceHigh confidence
US 9,988,673Nucleic Acid Production and Sequence Analysis
In force
 · High confidence
In forceHigh confidence
US 9,637,739RNA-DIRECTED DNA CLEAVAGE BY THE Cas9-crRNA COMPLEX
In force
 · High confidence
In forceHigh confidence
US 10,844,378RNA-DIRECTED DNA CLEAVAGE BY THE Cas9-crRNA COMPLEX
In force
 · High confidence
In forceHigh confidence
US 11,555,187RNA-DIRECTED DNA CLEAVAGE BY THE Cas9-crRNA COMPLEX
In force
 · High confidence
In forceHigh confidence
US 10,343,163System and Method for a Biomimetic Fluid Processing
In force
 · High confidence
In forceHigh confidence
US 10,590,373Systems and Methods for Biomimetic Fluid Processing
In force
 · Medium confidence
In forceMedium confidence
US 10,710,073System and Method for Biomimetic Fluid Processing
In force
 · Medium confidence
In forceMedium confidence
US 11,396,016System and Method for a Biomimetic Fluid Processing
In force
 · Medium confidence
In forceMedium confidence
10 of 32 patents shown.
Pro members see all 32.
Pro members: see all 32 patents
Also on record, not counted in the 32: 5 patents in force now held by others · 5 patents ended · 17 applications pending · 10 applications abandoned. List them

Sources and methods

Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 19, 2026 · includes USPTO assignment data published Nov 18, 2026, status data published Nov 19, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited